Q32 Bio (QTTB) to Post Earnings on Wednesday

Q32 Bio (NASDAQ:QTTB) will likely be posting its Q2 2026 results before the market opens on Wednesday, August 5th. Analysts expect Q32 Bio to post earnings of ($0.53) per share and revenue of $1.00 million for the quarter. Interested persons can check the company’s upcoming Q2 2026 earning report for the latest details on the call scheduled for Thursday, August 6, 2026 at 9:30 AM ET.

Q32 Bio (NASDAQ:QTTB) last posted its quarterly earnings data on Tuesday, May 5th. The company reported ($0.54) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.68) by $0.14. On average, analysts expect Q32 Bio to post $-2 EPS for the current fiscal year and $-2 EPS for the next fiscal year.

Q32 Bio Stock Down 5.1%

Shares of Q32 Bio stock traded down $0.80 during trading hours on Wednesday, hitting $14.91. 38,349 shares of the company’s stock traded hands, compared to its average volume of 787,221. The stock has a 50 day simple moving average of $12.71 and a 200-day simple moving average of $7.83. The company has a quick ratio of 5.36, a current ratio of 5.36 and a debt-to-equity ratio of 0.04. The company has a market cap of $252.89 million, a PE ratio of 5.61 and a beta of 0.24. Q32 Bio has a twelve month low of $1.57 and a twelve month high of $23.57.

Insider Transactions at Q32 Bio

In other news, Director Orbimed Advisors Llc acquired 1,875,000 shares of the stock in a transaction that occurred on Thursday, May 28th. The stock was purchased at an average cost of $8.00 per share, with a total value of $15,000,000.00. Following the completion of the acquisition, the director directly owned 3,502,987 shares in the company, valued at $28,023,896. This represents a 115.17% increase in their ownership of the stock. The acquisition was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. Also, Director Diyong Xu acquired 1,875,000 shares of the business’s stock in a transaction on Thursday, May 28th. The shares were purchased at an average price of $8.00 per share, for a total transaction of $15,000,000.00. Following the purchase, the director directly owned 3,502,987 shares of the company’s stock, valued at $28,023,896. This represents a 115.17% increase in their ownership of the stock. The SEC filing for this purchase provides additional information. 34.46% of the stock is currently owned by company insiders.

Institutional Investors Weigh In On Q32 Bio

Several institutional investors and hedge funds have recently made changes to their positions in the company. Marshall Wace LLP acquired a new stake in shares of Q32 Bio during the 2nd quarter valued at approximately $25,000. ADAR1 Capital Management LLC acquired a new position in Q32 Bio in the fourth quarter worth $66,000. XTX Topco Ltd bought a new stake in Q32 Bio during the fourth quarter valued at $68,000. HRT Financial LP increased its stake in Q32 Bio by 66.5% during the fourth quarter. HRT Financial LP now owns 24,698 shares of the company’s stock valued at $81,000 after purchasing an additional 9,862 shares during the last quarter. Finally, Jane Street Group LLC acquired a new stake in shares of Q32 Bio during the fourth quarter worth $84,000. 31.32% of the stock is owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

Several research firms have issued reports on QTTB. Oppenheimer lifted their price objective on Q32 Bio from $20.00 to $40.00 and gave the stock an “outperform” rating in a report on Monday, July 13th. Weiss Ratings upgraded Q32 Bio from a “sell (d+)” rating to a “hold (c-)” rating in a research note on Monday, May 11th. Mizuho initiated coverage on shares of Q32 Bio in a research report on Friday, May 22nd. They set an “outperform” rating and a $14.00 price target for the company. Zacks Research lowered shares of Q32 Bio from a “strong-buy” rating to a “hold” rating in a research note on Monday, May 18th. Finally, Cantor Fitzgerald assumed coverage on shares of Q32 Bio in a report on Monday, May 18th. They issued an “overweight” rating on the stock. Four equities research analysts have rated the stock with a Buy rating and two have assigned a Hold rating to the company’s stock. According to MarketBeat, the company currently has an average rating of “Moderate Buy” and an average price target of $30.00.

About Q32 Bio

Q32 Bio Inc, a clinical-stage biotechnology company, develops biologic therapeutics to restore healthy immune balance in patients with autoimmune and inflammatory diseases driven by pathological immune dysfunction in the United States. Its lead product candidate is ADX-097, a humanized anti-C3d monoclonal antibody fusion protein to restore complement regulation, which has completed Phase I clinical trial for the treatment of renal and other complement-mediated diseases of high unmet need, including lupus nephritis, immunoglobulin A nephropathy, complement component 3 glomerulopathy, and anti-neutrophil cytoplasmic antibody-associated vasculitis.